Data due by the end of the year from the phase Ib trial testing Proteostasis Therapeutics Inc.'s cystic fibrosis (CF) prospect PTI-428 could trigger moves by developers in the space looking to pair the drug with therapies such as Orkambi (lumacaftor/ivacaftor) from Vertex Pharmaceuticals Inc.